SLDB

Solid Biosciences Inc. SLDB

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-54.80M

Quarter to Jun 30

Free cash flow

$-52.74M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.14B total
RA CAPITAL MANAGEMENT, L.P.
$120.24M+28.9%
PERCEPTIVE ADVISORS LLC
$118.95M0.0%
Bain Capital Life Sciences Investors, LLC
$97.99M0.0%
Siren, L.L.C.
$76.83M0.0%
BlackRock, Inc.
$69.27M+39.8%
FMR LLC
$68.69M+90.7%
ARMISTICE CAPITAL, LLC
$42.74M+33.7%
STATE STREET CORP
$41.71M+271.0%
Jupiter Topco LLC
$40.38M--
VANGUARD CAPITAL MANAGEMENT LLC
$40.06MNew
RTW INVESTMENTS, LP
$38.89MNew
Deep Track Capital, LP
$35.61M0.0%
FRANKLIN RESOURCES INC
$34.37M+56.9%
CITADEL ADVISORS LLC
$28.12M+8.4%
Alyeska Investment Group, L.P.
$22.78M0.0%
AMERIPRISE FINANCIAL INC
$22.24M-8.7%
Vestal Point Capital, LP
$21.58M-56.8%
Redmile Group, LLC
$19.47M-3.1%
GEODE CAPITAL MANAGEMENT, LLC
$19.39M+49.8%
GOLDMAN SACHS GROUP INC
$16.01M+71.3%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$15.05M-14.2%
DIMENSIONAL FUND ADVISORS LP
$12.65M+32.4%
BLAIR WILLIAM & CO/IL
$7.56M+16.1%
VANGUARD PORTFOLIO MANAGEMENT LLC
$7.48MNew
Woodline Partners LP
$6.73M+36.2%
See all 158 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/SLDB

Earnings Per Share

13fpro.ai/company/SLDB

Loading ratio trend…

SLDB key financials by period

Reported revenue, net income and operating margin by fiscal year, from Solid Biosciences Inc.'s annual filings on SEC EDGAR.

Solid Biosciences Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2022$8.1M$-86.0M—
FY 2021$13.6M$-72.2M—
Source: SLDB filings on SEC EDGAR →

SLDB insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Solid Biosciences Inc. (SLDB): stock profile, AI score and financials

Solid Biosciences Inc. (SLDB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SLDB is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Solid Biosciences Inc. reports net income of $-54.8M, free cash flow of $-52.7M. Top institutional holders of SLDB by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS, Bain Capital Life Sciences Investors, based on the most recent SEC filings. SLDB trades on the Nasdaq exchange and files with the SEC under CIK 1707502. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLDB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Solid Biosciences Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1707502 →